Research progresses of vaccine and neutralizing antibody of respiratory syncytial virus
CSTR:
Author:
Affiliation:

Department of Pathology,National Health Commission Key Laboratory of Antibody Techniques,School of Basic Medical Sciences,Nanjing Medical University,Nanjing 211166 ,China

Clc Number:

R392.11

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Respiratory syncytial virus(RSV)mainly causes acute lower respiratory tract infections(ALRTI)in children,which is the main cause of death among children worldwide. At present,symptomatic treatment is the main treatment for RSV in clinical practice,while specific therapeutic drugs are relatively few. Therefore,the research and development of RSV vaccine or antibody drug is urgent and important. At the present stage,two RSV vaccines(Abrysvo and Arexvy)and two RSV monoclonal antibodies (Palivizumab and Nirsevimab)have been released to market,all of which showed good clinical efficacy in specific populations. In this review,the research progress of main vaccine types and neutralizing antibodies of RSV in recent years was reviewed,hoping to provide reference for the prevention and treatment of RSV.

    Reference
    Related
    Cited by
Get Citation

CUI Daixun, YANG Xiaohui, FENG Zhenqing. Research progresses of vaccine and neutralizing antibody of respiratory syncytial virus[J].,2024,(12):1763-1772.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 18,2024
  • Revised:
  • Adopted:
  • Online: December 16,2024
  • Published:
Article QR Code